Background: Aggressive familial giant-cell granulomas of the jaws can be severely deforming. Surgical and nonsurgical treatments may be associated with multiple recurrences. Denosumab, a new generation antiresorptive drug, is an osteoclast inhibitor, which may be particularly useful to manage such potentially disfiguring lesions. Materials and Methods: Two sisters, both with a history of multiple recurrent aggressive central giant-cell granuloma (CGCG)-like lesions in both jaws, were referred for management. All lesions were histologically consistent with the diagnosis of CGCG. The lesions were treated surgically with curettage and perilesional injection of triamcinolone. In particular, the older sister had four separate anatomic sites where some of her lesions had multiple recurrences necessitating three repeat procedures. A course of subcutaneous denosumab was administered following the last giant-cell granuloma removal in both sisters. Results: Bony healing was normal. No further recurrences were observed over 3.5 years of follow-up after denosumab therapy in either sister. Conclusions: In this small cohort comprising two sisters with multiple aggressive recurrent giant-cell granuloma lesions at multiple sites in the mouth, subcutaneous denosumab administration was associated with success over 3.5 years of follow-up. This report cautiously adds to the clinical experience in the use of denosumab for the treatment of recurrent aggressive familial CGCG lesions.
intRoDuction
Giant-cell tumors (GCTs) of bone are locally aggressive tumors found throughout the skeleton, in long bones, [1] [2] [3] bones of the hand [4] or feet, [5] and in the spine. [6] Central giant-cell granulomas (CGCGs) are locally aggressive oral cavity tumors with histology similar to other giant-cell lesions. [7, 8] CGCGs occur in the bones of the jaws while peripheral giant-cell granulomas occur in oral soft tissues. [9] CGCGs have been classified based on the clinical and radiographic findings. [10, 11] Their classification includes aggressive and nonaggressive or quiescent variants, which may also include a familial variety. [12] Aggressive familial CGCGs (AFCGCGs) of the jaws can be severely deforming and present with multiple recurrences. While these variants have been described, till date, there has been no molecular method of distinguishing the variants. [11] The recurrence rate of CGCGs managed with different lines of treatment is reported as ranging from 11% to 72%. [7] Surgical curettage or in aggressive lesions, resection are the most common therapies. [7, 13] However, even when using surgical curettage, undesirable damage to the jaws, nerves, or teeth and developing tooth buds may often prove to be unavoidable. Destructive recurrences are frequent. [7, 8] Therefore, alternative therapies such as intralesional injection of corticosteroids have been suggested. [7, 11, 14] Subcutaneous administration of calcitonin [15] or antiangiogenic therapy with interferon alpha was described in several case reports with variable success. [16] Unfortunately, randomized clinical trials regarding treatment outcomes of CGCGs are nonexistent. [13, 17] This retrospective review aims to describe two cases of AFCGCGs in siblings to add to the clinical experience of the use of denosumab, an antiresorptive medication which acts as an osteoclast inhibitor in the treatment of such rare lesions.
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Abstract

MateRials anD MethoDs
This study included two sisters both with a history of large, multiple, recurrent lytic lesions of the mandible and maxilla who were referred for the management of their giant-cell granulomas. The study was granted ethical approval as a retrospective study by the ethical committee of the Oulu University Hospital, and the data were treated according to the principles of the Helsinki Declaration.
Case 1
The older sister was 27 years of age at her initial presentation. Her first lesion was located in the left mandible at sites 33 and 34. The lesion was removed by extraction of tooth numbers 33 and 34 and by curettage. The lesion was found to be histologically consistent with a CGCG [ Figure 1 ].
Healing was complicated by a recurrence of the mandibular lesion 1 year later involving sites 34-42 and a new separate mandibular lesion at site 38. Both of these lesions were treated with curettage and the removal of teeth 32, 31, 41, and 42. In addition, tooth 38 was removed during the same operating session together with curettage of a new posterior Serum total and ionized calcium, phosphorus, parathyroid hormone (PTH), and alkaline phosphatase levels were all within normal limits. An ultrasound of the neck did not reveal any evidence of adenoma of the parathyroid glands. This sister was in her second trimester of pregnancy, so further radiographic tests were delayed. After uneventful delivery of her baby, the patient underwent cone beam computed tomography (CBCT) examination [ Figure 4 ] and bone and positron emission tomography (PET) scans with no additional skeletal lesions being identified [ Figure 5 ]. The decision was made to treat the patient with a single subcutaneous dose of 120 mg denosumab (XGEVA, Amgen, Thousand Oaks, California, USA). There was a recurrent lesion at tooth 14 which was extracted, and the area was infiltrated with triamcinolone 20 mg. The patient received a further course of three injections of 120 mg denosumab subcutaneously over 3 months. No further recurrences were noted over the next 3.5 years of active follow-up.
Case 2
The second sister was 29 years of age at the first presentation. She was noted to have two separate lytic lesions one in the maxilla at site 13 and another larger lesion in the mandible occupying sites 44, 45, 46, and 47 [ Figures 6 and 7 ]. A biopsy [ Figure 8 ] was consistent with CGCG [ Figure 9 ]. The two lesions were removed, and the perilesional tissues were injected with triamcinolone acetate 20 mg. Serum PTH, serum total and ionized calcium, phosphorus, alkaline phosphatase levels, and a PET scan were all within normal limits. Taking the aggressive history of her sister's tumors into account, the second sister was also offered denosumab treatment. She received a course of three injections of 120 mg denosumab subcutaneously over 3 months. No recurrences or new CGCG lesions were noted, since the denosumab administration, over the next 4 years of active follow-up.
Results
All lesions in both sisters were histologically consistent with the diagnosis of CGCGs. The lesions were treated surgically, with curettage and perilesional injection of triamcinolone. In particular, the older sister had four separate sites, in two jaws, where her lesions had multiple recurrences necessitating three repeat procedures. Denosumab treatment was administered as a first-time adjuvant dose 8 months following the last AFCGCG resection and the safe delivery of her baby. All surgical sites healed uneventfully without further recurrences.
Genetics
A genetics consultation was arranged. DNA analysis of both sisters was undertaken to rule out Cherubism and Noonan syndrome with scrutiny for the SH3BP2 gene and to rule out nonsense mutations of R234X exon 7 of the HRPT2 gene. Chromosomal mapping was performed to rule out any translocations.
Discussion
The recurrence rate of CGCGs managed with curettage, resection, intralesional steroid therapy, and calcitonin or antiangiogenic therapy is unacceptably high. [7] Denosumab is a new generation antiresorptive medication. It is an osteoclast inhibitor which radically differs from bisphosphonate medications. Some clinical trials in the orthopedic literature have shown that denosumab is a novel and effective therapeutic option for aggressive and recurrent GCTs in the spine and femur. [6, 18, 19] In GCTs, 13 consistently upregulated proteins and 19 consistently downregulated proteins have been identified in pre-and postdenosumab administration samples that were involved in the receptor activator of nuclear factor kappa B/RANK ligand (RANK/RANKL) pathway in patients with tumors located in the femur. [18] This suggests that these identified proteins may play a critical functional role in the osteolytic process of GCTs.
Denosumab has also been suggested to be useful in the management of potentially disfiguring recurrent CGCGs of the jaws. [20] [21] [22] [23] The authors of this current publication have used denosumab to treat the two sisters in this report with AFCGCGs. Denosumab is described as a fully human monoclonal antibody against the RANKL.
[6] Since giant-cell granulomas are rich in osteoclast-like cells, it seems logical that denosumab has potential in the management of such lesions. At the time of the writing of this manuscript, denosumab had been used in a total of 11 cases reported in the English literature thus far. [20] [21] [22] [23] Antiresorptive therapy is associated with the risk of osteonecrosis of the jaws (ONJs). [24] The frequency of ONJ in oncology patients receiving oncologic doses of bisphosphonate or denosumab is estimated at 1%-15%. The frequency in the osteoporosis patient population receiving much lower doses of bisphosphonate or denosumab is estimated at 0.001%-0.01%. [25] Nonetheless, a case of delayed wound healing resembling ONJ has been reported in one patient receiving denosumab treatment for an aggressive CGCG from a series of five cases. [20] Other adverse effects include nail changes and pain in the CGCG lesions during denosumab therapy. The pain is thought to be due to the active mineralization process with possible pressure on sensory nerves. [23] The reported dosage and duration of denosumab therapy vary in the literature. [20] [21] [22] [23] The effectiveness and response have been followed on the basis of patient symptoms and radiological parameters. The doses range from a single 120 mg dose to a series of three doses of 120 mg of subcutaneous denosumab to a longer course which is determined by the individual patient's response to denosumab treatment following PET, CT, or magnetic resonance imaging scans. [23] Denosumab has been used as adjuvant therapy in CGCGs where surgery has failed or was not possible. [20] [21] [22] [23] In the case of GCTs of the femur, when denosumab is given before surgery, the bone which subsequently replaced the GCT was found to be very dense and difficult to manage. Based on this observation in the femur with GCTs, it may be prudent to recommend that in the case of CGCGs of the jaws that denosumab be used as a postsurgical adjuvant therapy rather than preoperatively.
While there is a familial aspect in the history of aggressive CGCGs in these two sisters, neither sister possessed the gene for Cherubism or Noonan syndrome. [26, 27] No chromosomal translocations were found. 
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